Dr. Zevallos on Molecular Profile of HPV-Positive Oropharyngeal SCC Stratified by Smoking Status

Jose P. Zevallos, MD, MPH, FACS
Published: Saturday, Feb 20, 2016



Jose P. Zevallos, MD, MPH, FACS, assistant professor, director of Oncologic Research, University of North Carolina School of Medicine, discusses a study that examined the molecular profile of patients with HPV-positive oropharyngeal squamous cell carcinoma (SCC) stratified by smoking status.

Using targeted DNA sequencing, researchers sought to determine if patients with HPV-positive disease who were smokers had differing mutational status than those who were both HPV-positive and nonsmokers. 

Results showed that there were distinct genomic differences between HPV-positive nonsmokers and HPV-positive smokers. Smokers harbored mutations that mimicked HPV-negative tumors, he adds. This demonstrates that patients who are HPV-positive but have this genetic profile likely will not respond as well to treatment.

<<< View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium



Jose P. Zevallos, MD, MPH, FACS, assistant professor, director of Oncologic Research, University of North Carolina School of Medicine, discusses a study that examined the molecular profile of patients with HPV-positive oropharyngeal squamous cell carcinoma (SCC) stratified by smoking status.

Using targeted DNA sequencing, researchers sought to determine if patients with HPV-positive disease who were smokers had differing mutational status than those who were both HPV-positive and nonsmokers. 

Results showed that there were distinct genomic differences between HPV-positive nonsmokers and HPV-positive smokers. Smokers harbored mutations that mimicked HPV-negative tumors, he adds. This demonstrates that patients who are HPV-positive but have this genetic profile likely will not respond as well to treatment.

<<< View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x